Kathleen N Moore

Summary

Affiliation: University of Oklahoma Health Sciences Center
Country: USA

Publications

  1. ncbi Pathologic findings and outcomes for octogenarians presenting with uterine malignancy
    Kathleen N Moore
    University of Oklahoma Division of Gynecologic Oncology, 920 SL Young Blvd, Oklahoma City, OK 73103, USA
    Gynecol Oncol 106:572-8. 2007
  2. ncbi Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates
    Lisa M Landrum
    Section of Gynecology Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, P O Box 26901, WP 2410, Oklahoma City, OK 73190, USA
    Gynecol Oncol 108:342-7. 2008
  3. ncbi Uterine papillary serous carcinoma
    Kathleen N Moore
    Department of Gynecologic Oncology, University of Oklahoma, Oklahoma City, Oklahoma, USA
    Clin Obstet Gynecol 54:278-91. 2011
  4. ncbi Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes
    Kathleen Moore
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    Am J Obstet Gynecol 197:141.e1-6. 2007
  5. ncbi An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)
    Amanda Nickles Fader
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Cleveland Clinic, Cleveland, OH, USA
    Gynecol Oncol 115:244-8. 2009
  6. ncbi Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis
    Lisa M Landrum
    Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    Gynecol Oncol 112:337-41. 2009
  7. ncbi Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?
    Kathleen N Moore
    University of Oklahoma Health Sciences Center, Division of Gynecologic Oncology, Oklahoma City, Oklahoma 73103, USA
    Gynecol Oncol 110:133-9. 2008
  8. ncbi Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer
    Lisa M Landrum
    University of Oklahoma Health Sciences Center, Section of Gynecology Oncology, Oklahoma City, OK 73190, USA
    Gynecol Oncol 122:527-31. 2011
  9. ncbi Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes
    Amanda Nickles Fader
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A 81, Cleveland, Ohio 44195, USA
    Gynecol Oncol 112:558-62. 2009
  10. ncbi Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes
    Kathleen N Moore
    University of Oklahoma, Division of Gynecologic Oncology, 920 SL Young Boulevard, Oklahoma City, OK, USA
    Gynecol Oncol 108:466-71. 2008

Detail Information

Publications20

  1. ncbi Pathologic findings and outcomes for octogenarians presenting with uterine malignancy
    Kathleen N Moore
    University of Oklahoma Division of Gynecologic Oncology, 920 SL Young Blvd, Oklahoma City, OK 73103, USA
    Gynecol Oncol 106:572-8. 2007
    ..We evaluated prognostic, demographic and outcome data for patients>80 years old with uterine cancer (UC)...
  2. ncbi Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates
    Lisa M Landrum
    Section of Gynecology Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, P O Box 26901, WP 2410, Oklahoma City, OK 73190, USA
    Gynecol Oncol 108:342-7. 2008
    ..The purpose of this study was to review the completion rate of patients receiving i.p. chemotherapy as first line treatment at a single institution and determine what factors prohibit completion of therapy...
  3. ncbi Uterine papillary serous carcinoma
    Kathleen N Moore
    Department of Gynecologic Oncology, University of Oklahoma, Oklahoma City, Oklahoma, USA
    Clin Obstet Gynecol 54:278-91. 2011
    ..Treatment for UPSC typically entails surgery and in most women is followed by multimodality adjuvant therapy. In this review, we describe the epidemiology, natural history, treatment, and outcome of UPSC...
  4. ncbi Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes
    Kathleen Moore
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    Am J Obstet Gynecol 197:141.e1-6. 2007
    ..The purpose of this study was to evaluate histologic findings and outcomes among adolescents with cervical dysplasia...
  5. ncbi An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)
    Amanda Nickles Fader
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Cleveland Clinic, Cleveland, OH, USA
    Gynecol Oncol 115:244-8. 2009
    ..However, clinicopathologic risk factors for recurrence are not well understood. This study was undertaken to define the prognostic factors for recurrence and survival in patients with early-stage UPSC...
  6. ncbi Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis
    Lisa M Landrum
    Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    Gynecol Oncol 112:337-41. 2009
    ..The objective of this study is to evaluate overall survival (OS) and progression-free survival (PFS) in patients with advanced EC compared to a cohort of patients with OC matched for age and residual disease...
  7. ncbi Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?
    Kathleen N Moore
    University of Oklahoma Health Sciences Center, Division of Gynecologic Oncology, Oklahoma City, Oklahoma 73103, USA
    Gynecol Oncol 110:133-9. 2008
    ..Optimal management for very elderly women (>80) is unclear. This study sought to review the experience with treating ovarian cancer in this population...
  8. ncbi Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer
    Lisa M Landrum
    University of Oklahoma Health Sciences Center, Section of Gynecology Oncology, Oklahoma City, OK 73190, USA
    Gynecol Oncol 122:527-31. 2011
    ..CONCLUSIONS.: Although only 52% of patients were able to complete 6 cycles of cisplatin-based IP chemotherapy, significant reductions in cisplatin-related metabolic toxicity and catheter-related complications were noted...
  9. ncbi Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes
    Amanda Nickles Fader
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A 81, Cleveland, Ohio 44195, USA
    Gynecol Oncol 112:558-62. 2009
    ..To determine recurrence patterns and survival outcomes of stage II uterine papillary serous carcinoma (UPSC) patients treated by various modalities with an emphasis on carboplatin/paclitaxel-based chemotherapy (CT)+/-radiotherapy (RT)...
  10. ncbi Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes
    Kathleen N Moore
    University of Oklahoma, Division of Gynecologic Oncology, 920 SL Young Boulevard, Oklahoma City, OK, USA
    Gynecol Oncol 108:466-71. 2008
    ..To examine surgico-pathologic outcomes following extraperitoneal para-aortic lymph node dissection (EPLND) via pfannenstiel compared to paramedian incision prior to radiation in patients with cervical cancer...
  11. ncbi Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population?
    Kathleen N Moore
    Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, Oklahoma 73104, USA
    Cancer 115:1472-80. 2009
    ..In the current study, chemotherapy-related toxicity data were evaluated between patients aged > or = 80 years and those aged < 80 years...
  12. ncbi Cervical dysplasia in pregnancy: a multi-institutional evaluation
    Amanda N Fader
    Department of Obstetrics and Gynecology, Greater Baltimore Medical Center Johns Hopkins Medical Institutions, Baltimore, MD 21204, USA
    Am J Obstet Gynecol 203:113.e1-6. 2010
    ..This study was undertaken to identify the prognostic indicators associated with postpartum regression of cervical dysplasia diagnosed in pregnancy...
  13. ncbi Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary
    Kathleen N Moore
    University of Oklahoma, Division of Gynecologic Oncology, 920 SL Young Blvd, Oklahoma City, OK 73104, USA
    Gynecol Oncol 107:398-403. 2007
    ..Primary carcinoma of the fallopian tube (PCFT) is a rare malignancy comprising 1% of genital tract cancers. We sought to compare survival trends between PCFT and ovarian carcinoma (OC) patients (pts) in a matched, case-control comparison...
  14. ncbi Cervical dysplasia among women over 35 years of age
    Kathleen N Moore
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    Am J Obstet Gynecol 199:471.e1-5. 2008
    ..The objective of the study was to review the cytologic and histopathologic features among women 35 years of age or older with cervical dysplasia...
  15. ncbi Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis
    Kathleen N Moore
    Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, Oklahoma 73104, USA
    Cancer 116:5407-14. 2010
    ..This study evaluated whether progression-free interval (PFI) following primary chemotherapy (PCT) was predictive of overall survival (OS) after second-line chemotherapy in advanced/recurrent endometrial cancer (EC)...
  16. ncbi A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study
    Kathleen N Moore
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK 73190, USA
    Gynecol Oncol 127:456-61. 2012
    ..This study assessed the safety of chemoradiation with cetuximab in the treatment of women with newly diagnosed locally advanced cervical cancer...
  17. ncbi Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma
    Vladislav Zakharov
    Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
    Int J Clin Exp Pathol 3:608-17. 2010
    ..However, reduced AKR1C3 expression cannot distinguish hyperplastic endometrium from endometrial adenocarcinoma of endometrial type. The biologic and pathological roles of AKR1C3 in endometrial epithelium require further investigation...
  18. ncbi Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma
    Kathleen N Moore
    University of Oklahoma Health Sciences Center, 920 SL Young Blvd, WP 2470, Oklahoma City, OK, USA
    Gynecol Oncol 106:498-501. 2007
    ..To evaluate the rate of vesicovaginal fistula formation and mortality in women with Stage IVA cervical carcinoma...
  19. ncbi A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer
    Kathleen N Moore
    University of Oklahoma Health Sciences Center, 920 Stanton L Young Blvd WP 2470, Oklahoma City, OK 73014, and Washington University Barnes Jewish Christian Hospitals, St Louis, MO, USA
    Gynecol Oncol 105:299-303. 2007
    ..The objective of this study was to compare response rate and survival in patients with cervical cancer treated with PT or CT...
  20. ncbi Can frequency and severity of symptoms predict the presence of ovarian cancer?
    Kathleen N Moore
    University of Oklahoma, HSC, Oklahoma City, OK 73104, USA
    Nat Clin Pract Oncol 1:72-3. 2004